Prediction-Market Traders Betting Iran’s Fate: Fine Print Reminder
Prediction-market trading on Iran’s leadership surged as tensions flared, but unverified rumors triggered rapid price...
Articles — Page 1503
UroGen (URGN) 2025 Earnings: What Investors Should Know
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Near Protocol Surge Today? Why the Token Jumped 13%
NEAR token surged recently, signaling renewed market interest. This guide unpacks the drivers behind the near protoco...
Smart Money Piling Into AI Infrastructure Stock Now
A wave of institutional interest is reshaping AI infrastructure stocks. This guide explains why capital is flowing in...
Chart Industries Just Delivered Big EBITDA—Why Sell?
Chart Industries just delivered a sweeping earnings milestone, but a sizable investor trimmed a multi-million dollar ...
Rule Breaker Investing Mailbag: Listeners Speak Up Now
From AI tools reshaping research to currency risk and the tug of timing, the Rule Breaker Investing Mailbag surfaces ...
Terex Stock Surged Nearly 70%: Fund Exits $27M Stake
Terex stock surged nearly 70% in the last year, fueling headlines about strong demand in construction and industrial ...
AbbVie Stock Ultimate Option for Dividend Investors
Looking for a reliable income stream from stocks? This article examines why AbbVie may be the abbvie stock ultimate o...
Where Could Duolingo Years Be in Three Years? A 3-Year Investor Outlook
Duolingo has grown from a buzzy app to a profitable platform. This article explores three plausible paths for the nex...
Is Nvidia Stock Now? A Practical Guide to NVDA Investing
Nvidia powers the AI era, but is its stock a smart buy right now? This guide breaks down the fundamentals, compares c...
Is Crispr Therapeutics Stock Risky Right Now? A Practical Guide for Investors
Biotech stocks can swing on clinical data and regulatory news. This guide digs into whether crispr therapeutics stock...
Is It Too Late to Invest in Eli Lilly? Over 400% Years
Eli Lilly has powered higher for years, delivering eye-popping gains. But is there more room to run, or is it time to...